Cargando…

CAR-T cell therapy for hematological malignancies: History, status and promise

For many years, the methods of cancer treatment are usually surgery, chemotherapy and radiation therapy. Although these methods help to improve the condition, most tumors still have a poor prognosis. In recent years, immunotherapy has great potential in tumor treatment. Chimeric antigen receptor T-c...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Chao, Wang, Jianpeng, Che, Shusheng, Zhao, Hai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10658259/
https://www.ncbi.nlm.nih.gov/pubmed/38027932
http://dx.doi.org/10.1016/j.heliyon.2023.e21776
_version_ 1785137380119805952
author Wang, Chao
Wang, Jianpeng
Che, Shusheng
Zhao, Hai
author_facet Wang, Chao
Wang, Jianpeng
Che, Shusheng
Zhao, Hai
author_sort Wang, Chao
collection PubMed
description For many years, the methods of cancer treatment are usually surgery, chemotherapy and radiation therapy. Although these methods help to improve the condition, most tumors still have a poor prognosis. In recent years, immunotherapy has great potential in tumor treatment. Chimeric antigen receptor T-cell immunotherapy (CAR-T) uses the patient's own T cells to express chimeric antigen receptors. Chimeric antigen receptor (CAR) recognizes tumor-associated antigens and kills tumor cells. CAR-T has achieved good results in the treatment of hematological tumors. In 2017, the FDA approved the first CAR-T for the treatment of B-cell acute lymphoblastic leukemia (ALL). In October of the same year, the FDA approved CAR-T to treat B-cell lymphoma. In order to improve and enhance the therapeutic effect, CAR-T has become a research focus in recent years. The structure of CAR, the targets of CAR-T treatment, adverse reactions and improvement measures during the treatment process are summarized. This review is an attempt to highlight recent and possibly forgotten findings of advances in chimeric antigen receptor T cell for treatment of hematological tumors.
format Online
Article
Text
id pubmed-10658259
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-106582592023-11-07 CAR-T cell therapy for hematological malignancies: History, status and promise Wang, Chao Wang, Jianpeng Che, Shusheng Zhao, Hai Heliyon Review Article For many years, the methods of cancer treatment are usually surgery, chemotherapy and radiation therapy. Although these methods help to improve the condition, most tumors still have a poor prognosis. In recent years, immunotherapy has great potential in tumor treatment. Chimeric antigen receptor T-cell immunotherapy (CAR-T) uses the patient's own T cells to express chimeric antigen receptors. Chimeric antigen receptor (CAR) recognizes tumor-associated antigens and kills tumor cells. CAR-T has achieved good results in the treatment of hematological tumors. In 2017, the FDA approved the first CAR-T for the treatment of B-cell acute lymphoblastic leukemia (ALL). In October of the same year, the FDA approved CAR-T to treat B-cell lymphoma. In order to improve and enhance the therapeutic effect, CAR-T has become a research focus in recent years. The structure of CAR, the targets of CAR-T treatment, adverse reactions and improvement measures during the treatment process are summarized. This review is an attempt to highlight recent and possibly forgotten findings of advances in chimeric antigen receptor T cell for treatment of hematological tumors. Elsevier 2023-11-07 /pmc/articles/PMC10658259/ /pubmed/38027932 http://dx.doi.org/10.1016/j.heliyon.2023.e21776 Text en © 2023 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Review Article
Wang, Chao
Wang, Jianpeng
Che, Shusheng
Zhao, Hai
CAR-T cell therapy for hematological malignancies: History, status and promise
title CAR-T cell therapy for hematological malignancies: History, status and promise
title_full CAR-T cell therapy for hematological malignancies: History, status and promise
title_fullStr CAR-T cell therapy for hematological malignancies: History, status and promise
title_full_unstemmed CAR-T cell therapy for hematological malignancies: History, status and promise
title_short CAR-T cell therapy for hematological malignancies: History, status and promise
title_sort car-t cell therapy for hematological malignancies: history, status and promise
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10658259/
https://www.ncbi.nlm.nih.gov/pubmed/38027932
http://dx.doi.org/10.1016/j.heliyon.2023.e21776
work_keys_str_mv AT wangchao cartcelltherapyforhematologicalmalignancieshistorystatusandpromise
AT wangjianpeng cartcelltherapyforhematologicalmalignancieshistorystatusandpromise
AT cheshusheng cartcelltherapyforhematologicalmalignancieshistorystatusandpromise
AT zhaohai cartcelltherapyforhematologicalmalignancieshistorystatusandpromise